Oral ketamine for children with chronic pain: a pilot phase 1 study.

[1]  M. Grabois,et al.  Pediatric Analgesic Clinical Trial Designs, Measures, and Extrapolation: Report of an FDA Scientific Workshop , 2012, Pediatrics.

[2]  O. P. Tandon,et al.  Antagonism of stimulation-produced analgesia by naloxone and N-methyl-D-aspartate: role of opioid and N-methyl-D-aspartate receptors , 2012, Human & experimental toxicology.

[3]  P. McGrath,et al.  The epidemiology of chronic pain in children and adolescents revisited: A systematic review , 2011, PAIN.

[4]  H. Nakanishi,et al.  Microglial Ca2+-Activated K+ Channels Are Possible Molecular Targets for the Analgesic Effects of S-Ketamine on Neuropathic Pain , 2011, The Journal of Neuroscience.

[5]  A. Perez,et al.  Ketamine Activates the l-Arginine/Nitric Oxide/Cyclic Guanosine Monophosphate Pathway to Induce Peripheral Antinociception in Rats , 2011, Anesthesia and analgesia.

[6]  Erin R. Reichenberger,et al.  Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study , 2009, PAIN®.

[7]  J. Marinus,et al.  Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1 , 2009, PAIN.

[8]  C. Coté,et al.  Ketamine and neurotoxicity: clinical perspectives and implications for emergency medicine. , 2009, Annals of emergency medicine.

[9]  C. L. Baeyer,et al.  Three new datasets supporting use of the Numerical Rating Scale (NRS-11) for children’s self-reports of pain intensity , 2009, PAIN®.

[10]  R. Kurzrock,et al.  Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies , 2007, Cancer Chemotherapy and Pharmacology.

[11]  Tomasz R. Okon.  Ketamine: an introduction for the pain and palliative medicine physician. , 2007, Pain physician.

[12]  Bernard Laurent,et al.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4) , 2005, Pain.

[13]  J. Farrar,et al.  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[14]  S. Clarke,et al.  Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response , 2002, British Journal of Cancer.

[15]  V. D. Gupta.  Stability of Ketamine Hydrochloride Injection After Reconstitution in Water for Injection and Storagein 1-mL Tuberculin Polypropylene Syringes for Pediatric Use. , 2002, International journal of pharmaceutical compounding.

[16]  Y. Hijazi,et al.  Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[17]  S. Mercadante,et al.  Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. , 2000, Journal of pain and symptom management.

[18]  G. Lauretti,et al.  Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. , 1999, Journal of clinical anesthesia.

[19]  J. Peters,et al.  Modulation of cytochrome P-450 gene expression in endotoxemic mice is tissue specific and peroxisome proliferator-activated receptor-alpha dependent. , 1999, The Journal of pharmacology and experimental therapeutics.

[20]  G. Lauretti,et al.  Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. , 1999, Anesthesiology.

[21]  S. Ho,et al.  Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain , 1996, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[22]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[23]  L. Chauvelot‐Moachon,et al.  Acute‐phase response, interleukin‐6, and alteration of cyclosporine pharmacokinetics , 1994, Clinical pharmacology and therapeutics.

[24]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[25]  David J. Smith,et al.  Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro , 1987, Neuropharmacology.

[26]  J. Clements,et al.  PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINE , 1981 .